2017 EHA Annual Meeting Highlights

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: July 20, 2017
Expiration Date: July 20, 2018

Expected time to complete this activity as designed: 45 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, participants will hear key highlights taken from a select group of abstracts which focused on some of the most impactful data in Hodgkin lymphoma (HL) presented at the 2017 European Hematology Association (EHA) 22nd Congress. Leading experts in the field of HL will share their insights on a variety of abstracts, covering topics including, but not limited to: immunotherapy, PET imaging as a predictor of outcomes in advanced-stage cHL, and a report on the phase 3 trial looking at the possibility of treatment reduction in relation to negative interim PET findings.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with Hodgkin lymphoma (HL)
  • Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in HL
  • Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in HL


Successful Reduction in Treatment Intensity in Patients with Advanced-stage Hodgkin Lymphoma – Peter Borchmann, MD

Estimating the Efficacy of Novel Therapies in Classical Hodgkin Lymphoma – Paul Bröckelmann, MD

Evaluating the Efficacy of Nivolumab with and without Brentuximab Vedotin: New Trial Results and Treating Rare Lymphoma Cases: Effective Strategies for NHLPHL – Andreas Engert, MD

The Clinical Impact of PET-guided Treatment in Advanced-stage Hodgkin Lymphoma – Andrea Gallamini, MD

Overall Survival in Classical Hodgkin Lymphoma: Real-world Experiences in Kentucky – Hayder Saeed, MD

Early Trial Results of Combination Therapy with Brentuximab Vedotin in Hodgkin Lymphoma are Very Promising – Anas Younes, MD

Instructions for Participation and Credit

This activity is eligible for credit through July 20, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Peter Borchmann, MD
Assistant Medical Director
Department of Hematology/Oncology
University Hospital of Cologne
Cologne, Germany

Dr. Peter Borchmann is Assistant Medical Director in the Department of Hematology/Oncology at the University Hospital of Cologne where he is Head of the Lymphoma Program. He is also Co-Chairman of the German Hodgkin Study Group (GHSG) and responsible for development of investigator initiated clinical studies in Hodgkin lymphoma (HL). Dr. Borchmann’s scientific focus within the GHSG is to optimize the treatment of advanced stage HL patients and elderly patients. He is also the leader of the working group “Survivorship” (http://www.ghsg.org).

Paul Bröckelmann, MD
German Hodgkin Study Group (GHSG)
First Department of Internal Medicine
University Hospital of Cologne
Cologne, Germany

Dr. Paul Bröckelmann received his medical training at the University of Cologne, Germany. During medical school he completed internships at Universidad de Buenos Aires in Argentina, Cerrahpasa Medical Faculty Istanbul in Turkey, and at Brighton Sussex Medical School in England. Dr. Bröckelmann is working at the First Department of Internal Medicine, University Hospital of Cologne, and is a trial physician of the German Hodgkin Study Group (GHSG). He is Congress Secretary of the upcoming International Symposium on Hodgkin Lymphoma (ISHL11) to take place in Cologne in October 2018. Recently, he completed the Master Class of the European Hematology Association (EHA) and worked as a visiting physician with the lymphoma unit of the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City.

Andreas Engert, MD
Professor of Internal Medicine, Hematology, and Oncology
University Hospital of Cologne
Cologne, Germany

Dr. Andreas Engert received his medical degree and completed his medical training at Hannover Medical School and the University Hospital of Cologne (Germany). He is a Professor of Internal Medicine, Hematology, and Oncology at University Hospital of Cologne, Germany.

Dr. Engert worked at the Imperial Cancer Research Fund and the Royal Free Hospital in London, United Kingdom, on new immunotherapeutic approaches for cancer. He returned to Cologne to focus on developing antibody-based immunotherapy for patients with malignant lymphoma which resulted in a number of experimental phase I/II clinical trials. After he finished his postdoctoral lecture qualification, he was appointed consultant and became head of staff. He then became coordinating editor of the Cochrane Hematological Malignancies Group (CHMG) and vice director of the Department for Hematology and Oncology.

Dr. Engert has published more than 400 original papers in journals such as The New England Journal of Medicine, The Lancet Oncology, Nature Genetics, Journal of Clinical Oncology, and others. He served as secretary and was elected chairman of the German Hodgkin Study Group (GHSG). He was elected as councilor to the European Hematology Association (EHA) Board of Directors and later joined the EHA Executive Board. The University of Belgrade awarded Dr. Engert an honorary doctorate. For his scientific work, he has received a number of awards including the Ludwig-Heilmeyer-Medal, the Arthur-Pappenheim Award, the Research Award of the University of Cologne, the award of the German Cancer Society, and the Paul-Martini-Prize.

Andrea Gallamini, MD
Professor of Hematology
Department for Research, Medical Innovation & Statistics
A. Lacassagne Cancer Center
Nice, France

Dr. Andrea Gallamini received his medical degree from Genoa University in Italy. He completed fellowships at the Onco-Hematology Department of A. Lacassagne Hospital in Nice, France; Ferrokinetic Unit of Pavia University; Immuno-Rheumatology Department of Sait Eloi Hospital; MD Anderson Cancer Centre of Houston; and the Bone Marrow Transplantation Unit Hematology Department directed by Dr. A. Bacigalupo. In addition, Dr. Gallamini also completed a fellowship and was senior assistant in the Internal Medicine Department in Cuneo Hospital, and was senior assistant and head of hematology and bone marrow transplant in the Hematology Department of S. Croce Hospital in Cuneo. He is currently a Hematology Professor at the Research and Medical Innovation Department at Lacassagne Cancer Center in Nice, France.

Dr. Gallamini holds memberships in the American Society of Hematology (ASH) and the European Hematology Association (EHA). He is also a member of the FIL (Fondazione Italiana Linfomi) expert commission on peripheral T-cell lymphoma and Hodgkin lymphoma, coordinator of the clinical imaging commission of the FIL, a member of GITIL (Gruppo Italiano Terapie Innovative nei Linfomi), and coordinator of the Piedmont multicenter group for the study of invasive aspergillosis in hematological patients. In addition, Dr. Gallamini is a peer-reviewer for the Journal of Clinical Oncology, Blood, Annals of Oncology, Leukemia and Lymphoma, Haematologica, the Journal of Nuclear Medicine, and is on the editorial board of Leukemia and Lymphoma. His principal field of research interest is clinical management and functional imaging in Hodgkin lymphoma, and the clinical management of peripheral T-cell lymphoma.

Hayder Saeed, MD
Assistant Professor, Clinical Title Series
Department of Internal Medicine
Division of Hematology and Blood and Marrow Transplantation
University of Kentucky College of Medicine
Lexington, Kentucky

Dr. Hayder Saeed received his medical degree at the University of Baghdad College of Medicine. He completed an internal medicine residency, internship, and fellowship at the University of Kentucky Medical Center. He is an Assistant Professor, Clinical Title Series, Department of Internal Medicine/Division of Hematology and Blood and Marrow Transplantation at the University of Kentucky Medical Center.

Dr. Saeed is an American Board of Internal Medicine diplomate in internal medicine, hematology, and medical oncology. He holds memberships in the American Society of Clinical Oncology (ASCO), American Society of Hematology, American Society of Blood and Marrow Transplantation, and is on the ASCO University review panel. In addition, he is on the editorial board of Case Reports in Internal Medicine, and is a journal peer-review for Annals of Pediatrics and Child Health and Annals of Hematology. Dr. Saeed’s areas of clinical interest include allogeneic and autologous hematopoietic stem cell transplantation, and Hodgkin and non-Hodgkin lymphomas.

Anas Younes, MD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Dr. Anas Younes received his medical degree from the University of Damascus School of Medicine in Syria. He completed residencies in pathology at the Medical College of Ohio and in internal medicine at SUNY Downstate Medical Center, as well as a fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Younes is Chief of Memorial Sloan Kettering's Lymphoma Service, Division of Hematologic Oncology, where he is responsible for continuing to accelerate the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). He is also a Professor at Weill Cornell Medical College in New York City.

Dr. Younes serves on the Scientific Advisory Board of the Lymphoma Research Foundation. He is a past member of the National Cancer Institute Lymphoma Steering Committee. He has served as the principal investigator of more than 60 clinical trials and has led the National Cancer Institute-funded SPORE (Specialized Programs Of Research Excellence) in lymphoma both at MD Anderson Cancer Center and, most recently, at MSKCC. He is also the principal investigator of a SCOR grant supported by the Leukemia & Lymphoma Society. Dr. Younes has published more than 250 papers. His interests include HL, NHL, developing novel targeted therapies for lymphoma, identification of biomarkers for treatment, and participation in clinical trials. Dr. Younes led the trials that resulted in the FDA approval of brentuximab vedotin and nivolumab for the treatment of patients with relapsed Hodgkin lymphoma.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-157-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Peter Borchmann has received honoraria as a consultant from Bristol-Myers Squibb Company. He has received grant support related to research activities from Amgen Inc., F. Hoffmann-La Roche Ltd, Novartis AG, NPI, and Takeda Oncology.

Dr. Paul Bröckelmann has received honoraria as a consultant from Takeda Oncology. He has received grant support related to research activities from Bristol-Myers Squibb Company and Takeda Oncology.

Dr. Andres Engert has received honoraria as a consultant as well as grant support related to research activities from Affimed, Amgen Inc., Bristol-Myers Squibb Company, and Takeda Oncology.

Dr. Andrea Gallamini has disclosed no relevant financial relationships.

Dr. Hayder Saeed has disclosed no relevant financial relationships.

Dr. Anas Younes has received honoraria as a consultant from Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Inc., Incyte Corporation, Janssen Pharmaceuticals, Inc., Sanofi, Seattle Genetics, Inc., Merck & Co., Inc., and Takeda Oncology. He has received grant support related to research activities from Bristol-Myers Squibb, Curls, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., and Novartis AG.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.